Albireo Pharma Inc. is hoping to initiate a Phase III study for its lead candidate, the selective ileal bile acid transporter (IBAT) inhibitor A4250, in the rare genetic disease progressive familial intrahepatic cholestasis (PFIC) by the end of the year.
At the American Association for the Study of Liver Diseases meeting Oct
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?